ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access

Youness Kadil , Mohamed Mouhcine and Houda Filali

Laboratory of Pharmacology-Toxicology, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University of Casablanca, Morocco.
J Pure Appl Microbiol. 2020;14(suppl 1):1065-1071 | Article Number: 6230
Received: 22/04/2020 | Accepted: 09/05/2020 | Published: 28/05/2020

The COVID-19 caused by a new type of coronavirus has emerged from China and led to thousands of death globally. Despite the efforts engaged in studying this newly emerged virus and searching for its treatment, the understanding of the COVID-19 drug and target protein interactions still represent a key challenge. Several molecules have demonstrated In-Vitro activity against the SARS-CoV-2 virus and/or potential clinical benefit in observational and non-randomized studies. Randomized clinical trials of an appropriate size are currently ongoing to establish the efficacy of these therapeutic proposals. Herein, concerning these diverse guidelines and therapeutic suggestions of different approaches to the treatment, this research aims to provide a molecular analysis of the interaction between the principal molecules cited in bibliography and the active protease site of the virus.


COVID-19, Pharmacological treatment, Protease, docking, SARS-CoV2

Article Metrics

Article View: 437

Share This Article

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.